Clinigen Signs Exclusive Distribution Agreement with Cheplapharm to Distribute Etopophos and Vepesid in Australia and New Zealand
3 September 2019 - - UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) and German pharmaceutical company Cheplapharm Arzneimittel GmbH have signed an exclusive distribution agreement for chemotherapy products Etopophos and Vepesid in Australia and New Zealand, the companies said.
Cheplapharm acquired the global rights to the products from Bristol-Myers Squibb in August 2018. Cheplapharm has global capabilities in manufacturing and distribution and will continue to supply and provide access to these medicines for patients.
Clinigen has been appointed by Cheplapharm to distribute Etopophos and Vepesid via the Group's extensive infrastructure in Australia and New Zealand as part of Cheplapharm's network of exclusive cooperation partners.
Etopophos and Vepesid are etoposide products, a drug which is included on the World Health Organization Model List of Essential Medicines and is considered an essential medicine for priority diseases.
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with sites in North America, Europe, Africa and Asia Pacific.
In October 2018, the group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, a specialist pharmaceutical company in Switzerland.
Cheplapharm is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide.
The family-owned company specialises in selected active substances and indications and focuses on an international Buy and Build Strategy.